Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
WANDA PHIPATANAKUL · BOSTON CHILDREN'S HOSPITAL · 2020 · $301,999 — Project Summary/Abstract COVID-19, the infectious disease caused by SARS-CoV-2, is rapidly affecting humans around the globe. While initial epidemiological data have focused on cases that resulted in severe respiratory disease seen predominantly in adults, little information regarding the infection …
Ignacio E. Sanz · EMORY UNIVERSITY · 2020 · $525,608 — The COVID19 pandemic illustrates the urgent need for understanding human B cell responses to emergent pathogens and its application to assessing herd immunity. Our laboratories have described the phenotypic, immunological and molecular features of different arms of human B cell responses and in part…
James Dennis Neaton · UNIVERSITY OF MINNESOTA · 2020 · $4,517,512 — PROJECT SUMMARY INSIGHT is serving as lead clinical trials network for the development of a master protocol for trials of therapeutic neutralizing monoclonal antibodies (nMAbs) for patients hospitalized with COVID-19. Two NHLBI networks, PETAL and CTSN, the ACTG and Veterans Administration are colla…
David W Haas · VANDERBILT UNIVERSITY MEDICAL CENTER · 2020 · $558,406 — Project Summary Coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) required a rapid, coordinated response. The pandemic has interfered with many other important endeavors, including NIH-sponsored non-COVID HIV clinical trials. We need …
CRISTIAN APETREI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2020 · $705,280 — Abstract A coronavirus pandemic is currently in progress and a tremendous effort for developing effective vaccines to curb it is currently being made. Adenovirus (Ad)-based vaccines are in the lead in the clinical trials, and it is to be expected that at least one vaccine formulation will comprise o…
STUART A GANSKY · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $242,250 — Coronavirus Disease 2019 (COVID-19) is a pandemic currently without preventive or curative treatments, causing unprecedented disruption and costs to individuals and society. This COVID-19 Administrative Supplement to the “Coordinating Center to Help Eliminate/Reduce Oral Health Inequalities in Child…
Jeremiah James Faith · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $787,826 — PROJECT SUMMARY In approximately 6 months, the Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has resulted in >6 million cases and led to >350K deaths worldwide, with over 100K of these deaths in the USA alone. Although the major…
Marta Filizola · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $169,420 — PROJECT SUMMARY The coronavirus disease 2019 (COVID-19) pandemic that originated in Wuhan, China just a few months ago is advancing at an incredible rate in the United States and the rest of the world. It is impacting everyone's lives, as well as crippling the global economy, health care systems, an…
OFER LEVY · BOSTON CHILDREN'S HOSPITAL · 2020 · $2,174,014 — Project Summary/Abstract In Dec 2019, a cluster of respiratory illness in Wuhan China defined the onset of a worldwide pandemic involving a novel coronavirus (SARS-CoV-2). SARS-CoV-2 infected patients are frequently asymptomatic, but initial epidemiologic estimates from the WHO indicate that ~15% of…
Ming-Ming Zhou · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $342,914 — PROJECT SUMMARY This administrative supplement application is submitted for the parent award (5R01AI124465) in response to NIAID’s Notice of Special Interest (NOT-AI-20-031) “Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)”, as well as “Administrati…
STEVEN E REIS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2020 · $842,907 — ABSTRACT The pandemic caused by the SARS-CoV-2 virus continues to impact public health and the health of individuals, families, and communities. Those with a rare disease may be disproportionately affected because they may have a high risk of exposure to SARS-CoV-2 from their caregivers, housing sit…
Margaret Juliana McElrath · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $29,952,323 — This proposal outlines the scientific agenda for the Leadership and Operations Center of the HIV Vaccine Trials Network (HVTN), the collaboration of physician scientists at 64 clinical trial sites in 15 countries on 4 continents dedicated to developing globally effective vaccines for HIV, tuberculos…
DOUGLAS K OWENS · STANFORD UNIVERSITY · 2020 · $380,547 — Project Summary/Abstract In 2019, our competitive renewal for our NIDA-funded work on opioids, HIV, and HCV was funded with a MERIT award. In this supplement to our MERIT grant, we will address pressing issues in vulnerable populations at risk from SARS-CoV-2. We will adapt the modeling frameworks w…
Deborah J Donnell · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $295,993 — Abstract The proposed research, CoVPN 5002, will directly contribute to preparedness for SARS-CoV-2 vaccine and other COVID-19 prevention and treatment studies by determining the prevalence of SARS-CoV-2 infection and seroprevalence among samples of individuals at elevated risk as well as the genera…
DAVID C. HESS · AUGUSTA UNIVERSITY · 2020 · $308,000 — The SARS-CoV-2 virus, like other coronaviruses, is neurotropic. A clue to early invasion and involvement of the nervous system in COVID-19 patients are the early symptoms of anosmia and hypogeusia. These may be seen in over 60% of COVID-19 positive patients. There is evidence from the humanized ACE2…
Peter Grayson · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · 2020 · $1,522,745 — Recruitment to date remains strong within the Vasculitis Natural History Study. All patients seen at the NIH Clinical Center receive comprehensive clinical evaluation and contribute samples to a growing biobank. Over the last year, we have focused on two forms of vasculitis: large vessel vasculitis …
Sonja Best · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $243,355 — The emergence of SARS-CoV-2 rapidly became a global pandemic necessitating the need to understand the mechanisms of disease, and develop vaccines and therapeutics. These efforts are hampered by the fact that the most useful experimental model in these efforts, the mouse, is not susceptible to infect…
Andrea Lisco · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $2,622 — The extraordinarily wide spectrum of clinical manifestations associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, ranging from asymptomatic to fatal disease, represent an unexpected and unexplained clinical feature for an emerging highly contagious novel human path…
Michael Grigg · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $83,030 — Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the etiologic agent of COVID-19, emerged in 2019 as a public health emergency and global pandemic. SARS-CoV-2 is a linear, non-segmented, capped, polyadenylated positive-sense, single stranded RNA virus related to SARS-CoV and MERS-CoV, t…
Carrie Mae Long · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $880,868 — Coxiella burnetii is a bacterium that can cause a severe flu-like illness in humans known as Q fever. This zoonotic infection is typically acquired via aerosol transmission of contaminated byproducts of infected ruminants. The pronounced infectivity and environmental stability of C. burnetii highli…